JP2023513156A5 - - Google Patents

Info

Publication number
JP2023513156A5
JP2023513156A5 JP2022547671A JP2022547671A JP2023513156A5 JP 2023513156 A5 JP2023513156 A5 JP 2023513156A5 JP 2022547671 A JP2022547671 A JP 2022547671A JP 2022547671 A JP2022547671 A JP 2022547671A JP 2023513156 A5 JP2023513156 A5 JP 2023513156A5
Authority
JP
Japan
Prior art keywords
cells
car
hapten
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547671A
Other languages
English (en)
Japanese (ja)
Other versions
JP7744914B2 (ja
JP2023513156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016194 external-priority patent/WO2021158534A1/en
Publication of JP2023513156A publication Critical patent/JP2023513156A/ja
Publication of JP2023513156A5 publication Critical patent/JP2023513156A5/ja
Application granted granted Critical
Publication of JP7744914B2 publication Critical patent/JP7744914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547671A 2020-02-04 2021-02-02 ハプテン標識細胞によりキメラ抗原受容体t細胞を刺激する方法およびそのための組成物 Active JP7744914B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969917P 2020-02-04 2020-02-04
US62/969,917 2020-02-04
PCT/US2021/016194 WO2021158534A1 (en) 2020-02-04 2021-02-02 Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells

Publications (3)

Publication Number Publication Date
JP2023513156A JP2023513156A (ja) 2023-03-30
JP2023513156A5 true JP2023513156A5 (cg-RX-API-DMAC10.html) 2024-02-09
JP7744914B2 JP7744914B2 (ja) 2025-09-26

Family

ID=77200468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547671A Active JP7744914B2 (ja) 2020-02-04 2021-02-02 ハプテン標識細胞によりキメラ抗原受容体t細胞を刺激する方法およびそのための組成物

Country Status (9)

Country Link
US (1) US20230172981A1 (cg-RX-API-DMAC10.html)
EP (1) EP4100026A4 (cg-RX-API-DMAC10.html)
JP (1) JP7744914B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220164474A (cg-RX-API-DMAC10.html)
CN (1) CN115397440A (cg-RX-API-DMAC10.html)
AU (1) AU2021216554A1 (cg-RX-API-DMAC10.html)
CA (1) CA3169804A1 (cg-RX-API-DMAC10.html)
IL (1) IL295074A (cg-RX-API-DMAC10.html)
WO (1) WO2021158534A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) * 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
US20250195651A1 (en) * 2022-03-15 2025-06-19 Celledit Llc Use of antigen presenting cells to enhance car-t cell therapy
WO2024206913A2 (en) * 2023-03-31 2024-10-03 Northwestern University Compositions for antigen-specific immune cell activation
EP4724087A1 (en) * 2023-06-06 2026-04-15 Danmarks Tekniske Universitet A synthetic cellular advanced signal adapter (scasa) system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004052A1 (en) * 1990-05-08 2002-01-10 David Berd Composition comprising a tumor cell extract and method of using the composition
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
KR20180095511A (ko) * 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 표적화된 암 요법
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
JP7078937B2 (ja) * 2016-12-21 2022-06-01 ダンマークス テクニスク ユニバーシテット 免疫細胞を操作するための抗原提示足場
AU2018219226B2 (en) * 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
KR20210074274A (ko) * 2018-08-06 2021-06-21 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물

Similar Documents

Publication Publication Date Title
Song et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)
Yeku et al. Adoptive T-cell therapy for solid tumors
Liu et al. Targeting alpha-fetoprotein (AFP)–MHC complex with CAR T-cell therapy for liver cancer
JP5414750B2 (ja) 治療および診断用抗Hsp70抗体
JP2021513961A5 (cg-RX-API-DMAC10.html)
US20230302155A1 (en) Compositions and methods for in vivo generation of car expressing cells
CN108603200B (zh) 优化的慢病毒转移载体及其用途
KR20210134339A (ko) 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
JP2021502104A5 (cg-RX-API-DMAC10.html)
Rodriguez-Garcia et al. T-cell target antigens across major gynecologic cancers
CN108290955A (zh) 人源化抗-cll-1抗体
CN115397440A (zh) 用半抗原标记细胞刺激嵌合抗原受体t细胞的方法和组合物
JP2021505637A5 (cg-RX-API-DMAC10.html)
JP7541390B2 (ja) 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途
Vanhooren et al. TARP as antigen in cancer immunotherapy
Xia et al. Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy
Mashayekhi et al. Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers
JP2025515324A5 (cg-RX-API-DMAC10.html)
KR102562878B1 (ko) 질환 항원이 융합된 단백질 및 이의 용도
CN118786142A (zh) 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞
CN114853897A (zh) 抗cd19/cd22/cd3三特异性抗体及用途
CN114763387A (zh) 一种基于结构优化蛋白活性的三特异性抗体制备方法
WO2024148216A2 (en) Combination therapy with t cell engager
JP2025511909A (ja) Itgb2媒介薬物伝達システム
JP2025512377A5 (cg-RX-API-DMAC10.html)